These Analysts Increase Their Forecasts On Biogen After Upbeat Q3 Results
Avi Kapoor 4 days ago
MarketsTrading IdeasPre-Market OutlookNewsAnalyst RatingsPrice TargetEarnings
Biogen beats Q3 estimates, narrows FY2026 EPS outlook, and sees analysts raise price targets to $290; shares dip 0.3% premarket.
Biogen Inc (NASDAQ:BIIB) on Wednesday posted better-than-expected earnings for the third quarter.
The company posted adjusted earnings of $2.62 per share, beating market estimates of $1.98 per share. The company’s sales came in at $2.804 billion versus expectations of $2.632 billion.
Biogen narrowed its FY2026 adjusted EPS guidance from $15.85-$16.85 to $15.95-$16.75.
Biogen shares fell 0.3% to $243.34 in pre-market trading.
These analysts made changes to their price targets on Biogen following earnings announcement.
- Needham analyst Ami Fadia maintained the stock with a Buy and raised the price target from $256 to $290.
- Baird analyst Brian Skorney maintained the stock with an Outperform rating and raised the price target from $250 to $290.
Considering buying BIIB stock? Here’s what analysts think:
Photo via Shutterstock